文献速递妇科

上皮性卵巢癌脑转移与BRCA1/2突变状态的关系

Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
PubMed 文献 · Gynecol Oncol · 2019-05-18

单中心回顾性研究分析2008年1月1日至2018年7月1日3649例上皮性卵巢癌患者,其中91例(2.5%)发生脑转移;63例有胚系突变信息,21例(35%)携带BRCA1/2突变。BRCA突变组脑转移时孤立病灶比例更高(48% vs 19%,p=0.02),脑转移后生存29个月 vs 9个月,校正HR 0.53(95%CI 0.25-1.11,p=0.09)。

要点

  • 3649例上皮性卵巢癌中91例(2.5%)发生脑转移。
  • BRCA突变组脑转移时为孤立病灶者48%(10例)vs 野生型19%(8例),p=0.02。
  • 脑转移后生存BRCA突变组29个月 vs 野生型9个月,校正HR 0.53(95%CI 0.25-1.11,p=0.09)。

核心结论

  • 这是迄今比较上皮性卵巢癌脑转移患者按突变状态结局的最大研究。
  • BRCA突变患者更可能为孤立脑转移,可能是其生存期长的因素。
  • 这支持对BRCA突变上皮性卵巢癌脑转移患者积极治疗。
  • 需要进一步研究BRCA突变状态与脑转移的相关性。

研究设计与样本

  • 单中心回顾性研究,从两个机构数据库识别2008年1月1日至2018年7月1日治疗的上皮性卵巢癌、fallopian tube及原发腹膜癌伴脑转移患者。
  • 回顾病历和医疗记录获取临床特征和胚系BRCA突变状态。
  • 3649例上皮性卵巢癌患者中91例(2.5%)发生脑转移;63例(69%)有胚系突变信息,其中21例(35%)携带BRCA1/2突变(15例BRCA1,6例BRCA2)。

主要发现

  • 两组临床特征相似。
  • 脑转移诊断中位时间:BRCA突变组31个月(95%CI 22.6-39.4)vs 野生型组32个月(95%CI 23.7-40.3),p=0.78。
  • 脑转移诊断时脑转移为唯一疾病证据者:BRCA突变组48%(10例)vs 野生型组19%(8例),p=0.02。
  • 脑转移治疗按突变状态无差异(p=0.84)。
  • 脑转移诊断后生存:BRCA突变组29个月(95%CI 15.5-42.5)vs 野生型组9个月(95%CI 5.5-12.5),校正HR 0.53(95%CI 0.25-1.11),p=0.09;HR校正脑转移诊断时全身疾病存在。

临床怎么用

  • 作者认为这支持对BRCA突变上皮性卵巢癌脑转移患者积极治疗。
  • 作者认为需要进一步研究BRCA突变状态与脑转移的相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate clinical outcomes of patients with BRCA-associated ovarian cancer who developed brain metastases (BM). METHODS: Patients with epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC) and BM, treated at a single institution from 1/1/2008-7/1/2018, were identified from two institutional databases. Charts and medical records were retrospectively reviewed for clinical characteristics and germline BRCA mutation status. Appropriate statistics were used. RESULTS: Of 3649 patients with EOC, 91 had BM (2.5%). Germline mutation status was available for 63 (69%) cases; 21 (35%) of these harbored a BRCA1/2 mutation (15 BRCA1, 6 BRCA2). Clinical characteristics were similar between groups. BM were diagnosed at a median of 31 months (95% CI, 22.6-39.4) in BRCA-mutated (mBRCA) and 32 months (95% CI, 23.7-40.3) in wild-type BRCA (wtBRCA) (p = 0.78) patients. Brain metastases were the only evidence of disease at time of BM diagnoses in 48% (n = 10) mBRCA and 19% (n = 8) wtBRCA (p = 0.02) patients. There was no difference in treatment of BM by mutation status (p = 0.84). Survival from time of BM diagnosis was 29 months (95%CI, 15.5-42.5) in mBRCA and 9 months (95% CI, 5.5-12.5) in wtBRCA patients, with an adjusted hazard ratio (HR) of 0.53, p = 0.09; 95% CI, 0.25-1.11. HR was adjusted for presence of systemic disease at time of BM diagnosis. CONCLUSION: This is the largest study to date comparing outcomes in patients with EOC and BM by mutation status. mBRCA patients were more likely to have isolated BM, which may be a factor in their long survival. This supports the pursuit of aggressive treatment for mBRCA EOC patients with BM. Additional studies examining the correlation of BRCA mutational status with BM are warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Stasenko M, Cybulska P, Feit N, et al. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecol Oncol. 2019. PMID: 31113680. doi:10.1016/j.ygyno.2019.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。